Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
7 facts about this weight loss drugs that actually work
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.
Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drugs
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Eli Lilly's weight loss pill could get federal approval by early next year
Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks told Bloomberg News on Monday that data on the drug, orforglipron, is expected before the middle of 2025.
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
What is Mounjaro? Everything to know about NHS approved weight loss jab
Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...
Lilly Shares on Track for Worst Day Since 2021 After Downbeat Zepbound Sales Forecast
The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...
Insider Monkey6h
Why Eli Lilly (LLY) Stock Is Declining Today
Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker estimated ...
What's in the 'Natural Mounjaro' Drink — and Should You Try It?
"We're suckers for quick fixes," Emily Feivor, a registered dietician, tells PEOPLE about the claim that honey, lemon, water, ...
Evening Standard on MSN23h
Celebrities who’ve used Ozempic: Oprah Winfrey, James Corden, and more
While talk show queen Oprah Winfrey has declined to name the brand she uses, she’s among the Hollywood stars who have been ...
What is Mounjaro and who will be eligible for it on the NHS?
Weight-loss injection Mounjaro, or tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this ...